Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MBOAT4 | Q96T53 | 20/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22968360 | 0.85 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL21223998 | 0.82 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL22968385 | 0.80 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL21223042 | 0.80 | MBOAT4 (0.71) | MBOAT4 | |
| SCHEMBL21223118 | 0.80 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL24590743 | 0.79 | MBOAT4 (0.86) | MBOAT4 | |
| SCHEMBL22968359 | 0.77 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL22968378 | 0.77 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL22968408 | 0.74 | MBOAT4 (1.00) | MBOAT4 | |
| SCHEMBL24129810 | 0.73 | MBOAT4 (0.58) | MBOAT4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111683951-B | Triazolopyrimidine derivatives useful as ghrelin O-acyltransferase (GOAT) inhibitors | 勃林格殷格翰国际有限公司 | 2023-10-13 | — | — | CN | disclosed |
| US-11583532-B2 | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-21 | — | — | US | disclosed |
| US-11583532-B2 | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-02-21 | — | — | US | disclosed |
| EP-3746443-B1 | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2022-07-06 | — | — | EP | disclosed |
| US-20210038603-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2021-02-11 | — | — | US | disclosed |
| US-20210038603-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2021-02-11 | — | — | US | disclosed |
| EP-3746443-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2020-12-09 | — | — | EP | disclosed |
| WO-2019149660-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
| WO-2019149660-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210038603-A1 | TRIAZOLOPYRIMIDINE DERIVATIVES FOR USE AS GHRELIN O-ACYL TRANSFERASE (GOAT) INHIBITORS | MBOAT4, GIPR, MTTP | MBOAT4 1/4885 |
| US-11583532-B2 | Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors | MBOAT4, GIPR, MTTP | MBOAT4 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.